Abstract:Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal of all cancer types. A key — yet poorly understood — facet in the disease state is cachexia, a multi-organ pathological state characterized by physical wasting and tissue catabolism. It occurs in 80% of PDAC patients, and to date there are no preventative or early detection methods. Cachexia leads to limited tolerance to anti-cancer therapy and contributes to disease lethality. Here, we present the first-of-its-kind systemic metabolomic analysis across cachectic stages to better understand disease progression. We used the well-established mutant KRASG12D(LSL/+) mutant p53 inducible mouse model of PDAC. Model physiology faithfully recaptures human cachexia: we observe progressive overall weight loss as well as loss of skeletal muscle and adipose tissue. As with human disease, weight loss occurs prior to loss of appetite in the animals, suggesting physiological changes independent of nutrition. Importantly, our model captures the period prior to weight loss (pre-CAC), as well as early-CAC ( 10% weight loss). We profiled the metabolomes of the pancreas, interstitial fluid, plasma, liver, 3 different adipose tissues, and 3 skeletal muscles, from male and female mice, control and tumor-bearing, across all 3 stages of cachexia. Each tissue has a unique metabolic trajectory across cachexia stages; pathway and correlation analyses showed a particular emphasis on lipid alterations in peripheral tissues. Strikingly, we find systemic metabolic changes prior to tissue wasting, including rewiring in the liver before the presence of metastases. This indicates systemic alterations as early as pre-CAC. We therefore used computational modeling to identify metabolites that may be participating in cross-tissue networks. A key finding, confirmed by 13C tracing, was the circulation of lactate and glucose and their uptake by the liver and pancreas. Network maps also suggest lipid rewiring in distal tissues, changes in abundances of these same lipid species in plasma, and their consequent alterations in the tumor and liver. A fundamental question remains: can we predict cachexia development before the manifestation of symptoms? We used feature selection algorithms based on statistical learning, training the models only on a subset of data. Specific sphingolipids and triglycerides were the key lipid species that distinguished control and pre-CAC. We find that the model — trained only on pre-CAC — is able to determine early-CAC with an 85% accuracy and late-CAC with a 90% accuracy. Thus, a limited set of metabolites that are altered in pre-CAC could have predictive value for future cachexia development. Overall, our work provides a resource for the field and advances our understanding of systemic metabolism in PDAC cachexia. We hope this will lay the foundation for cachexia prevention and treatment. Citation Format: Deepti Mathur, Blanca Majem, Courtney Beaulieu, Lucas Dailey, Sarah Jeanfavre, Joao Xavier, Clary Clish, Nada Kalaany. Metabolic patterns of pancreatic cancer cachexia: Cross-tissue lipid networks predict cachexia progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6610.

Longitudinal Muscle Biopsies Reveal Inter- and Intra-Subject Variability in Cancer Cachexia: Paving the Way for Biopsy-Guided Tailored Treatment

Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia model

A Time-Course Comparison of Skeletal Muscle Metabolomic Alterations in Walker-256 Tumour-Bearing Rats at Different Stages of Life

A novel orthotopic mouse model replicates human lung cancer cachexia

Low dose orthotopic cancer implantation permits measurement of longitudinal functional changes associated with cachexia

Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine

New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss

Skeletal muscle adaptations in patients with lung cancer: Longitudinal observations from the whole body to cellular level

Transcriptomic signature of cancer cachexia by integration of machine learning, literature mining and meta-analysis

Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade

Stage-specific Muscle Wasting Mechanisms in a Novel Cancer Cachexia Mouse Model for Ovarian Granulosa Cell Tumor

Integrated Analysis of Serum and Intact Muscle Metabonomics Identify Metabolic Profiles of Cancer Cachexia in A Dynamic Mouse Model

Dual Energy X-ray Absorptiometry (DEXA) as a longitudinal outcome measure of cancer-related muscle wasting in mice

Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia—the effects of blocking myostatin and activins

Abstract 6610: Metabolic patterns of pancreatic cancer cachexia: Cross-tissue lipid networks predict cachexia progression

Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies

Development of skeletal muscle fibrosis in a rodent model of cancer cachexia

Prognostic value of deep learning-derived body composition in advanced pancreatic cancer—a retrospective multicenter study

Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials

Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia

Towards a fully automatic workflow for investigating the dynamics of lung cancer cachexia during radiotherapy using cone beam computed tomography